SCH 530348: a novel oral thrombin receptor antagonist.
SCH 530348, a synthetic tricyclic 3-phenylpyridine, is an orally active fourth generation himbacine-based antagonist of the protease-activated receptor (PAR)-1, the primary receptor for thrombin on platelets in humans. SCH 530348 is the first in a new class of compounds that inhibit thrombin-mediated platelet aggregation without affecting the enzymatic activity of thrombin on fibrinogen. Preclinical and initial clinical studies have demonstrated this compound to be a highly potent inhibitor of thrombin-induced platelet activation, to have excellent oral bioavailability and to have a favorable safety profile. These data suggest that this compound has the potential to reduce the risk of ischemic events without significantly increasing the rate of bleeding. Two large Phase III clinical outcome trials are currently underway to evaluate the safety and efficacy of SCH 530348 for the management of acute coronary syndromes and the secondary prevention of atherothrombotic events.
Bonaca
Marc P
MP
TIMI Study Group, Brigham & Women's Hospital, Boston, MA 02115, USA. mbonaca@partners.org
Morrow
David A
DA
D054058:Acute Coronary Syndrome / Q000188:drug therapy*; D003328:Coronary Thrombosis / Q000188:drug therapy; D006801:Humans; D007783:Lactones / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D010974:Platelet Aggregation / Q000187:drug effects*; D011725:Pyridines / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D044463:Receptor, PAR-1 / Q000187:drug effects; D018179:Receptors, Thrombin / Q000037:antagonists & inhibitors* / Q000187:drug effects; D013923:Thromboembolism / Q000188:drug therapy; D010975:Platelet Aggregation Inhibitors
D007783:Lactones; D011725:Pyridines; D044463:Receptor, PAR-1; D018179:Receptors, Thrombin; C058323:3-phenylpyridine; C530299:vorapaxar; D010975:Platelet Aggregation Inhibitors